Session Information
Session Type: Poster Session C
Session Time: 10:30AM-12:30PM
Background/Purpose: The vasculitides are rare but serious conditions that are characterized by the destructive inflammation of the blood vessels. Patients living with vasculitis are often considered immunocompromised and require immunosuppression for the management of their condition. As of result of these two factors, there is increased risk of vaccine preventable disease in these patients. In our study we looked the baseline rate of vaccination in our vasculitis patients and implemented a multidisciplinary approach involving the patient’s community pharmacy to improve the rate of vaccination from baseline.
Methods: Patients were initially recruited to build a vaccination database to determine the baseline vaccination status against Pneumonia (PPSV23, PCV13, PCV20), Shingles (RZV), Tetanus (Tdap), Hepatitis B, COVID-19, and Influenza. This information was used to determine the baseline vaccination rates for our practice. Patients were then contacted and provided with an overview and education of their missing vaccinations. Patients who agreed to participate had their pharmacy of choice contacted by a member of the study team to organize for the missing vaccinations. The vaccination status of patients in the database was reviewed at the one year to determine what improvements occured in the overall rate of vaccination. Patients with a incomplete/partial vaccine status were contacted to determine reasons for missing vaccinations and provide assistance in completing vaccine series (contacting pharmacy again, referral to public health, etc.).
Results: 103 patients participated in VIVA QI.
The baseline rate of vaccination were as follows
|
Unvaccinated |
Partially Vaccinated |
Vaccinated |
|
|
Pneumovax 23 (PPSV23) |
46/103 (45%) |
N/A |
57/103 (55%) |
|
Prevnar 13 (PCV13) |
59/103 (57%) |
44/103 (43%) |
|
|
Shingles (RZV) |
79/103 (77%) |
6/103 (6%) |
18/103 (17%) |
|
Tetanus (Tdap) |
47/103 (46%) |
N/A |
56/103 (54%) |
|
Hepatitis B (HepB) |
51/103 (50%) |
4/103 (4%) |
47/103 (46%) |
|
COVID-19 |
15/103 (15%) |
48/103 (47%) |
40/103 (39%) |
|
Influenza (IIV3, IIV4) |
88/103 (85%) |
N/A |
15/103 (15%) |
Partial vaccination was defined as follows: in shingles was defined as receiving 1 out 2 vaccines in the series, in hepatitis B receiving less than 3 vaccines, and in COVID-19 receiving less than 3 mRNA vaccinations.
After one year, the vaccination rates were as follows:
|
Unvaccinated |
Partially Vaccinated |
Vaccinated |
|
|
Pneumovax 23 (PPSV23) |
30/103 (29%) |
N/A |
73/103 (71%) |
|
Prevnar 13 (PCV13) or Prevnar 20 (PCV 20) |
48/103 (47%) |
N/A |
55/103 (53%) |
|
Shingles (RZV) |
69/103 (67%) |
3/103 (3%) |
31/103 (30%) |
|
Tetanus (Tdap) |
33/103 (32%) |
N/A |
70/103 (68%) |
|
Hepatitis B (HepB) |
44/103 (43%) |
4/103 (4%) |
55/103 (53%) |
|
COVID-19 |
8/103 (8%) |
28/103 (27%) |
67/103 (65%) |
|
Influenza (IIV3, IIV4) |
53/103 (51%) |
N/A |
50/103 (49%) |
Conclusion: In this study, vaccination rates increased in all vaccines included. The greatest improvement in vaccination rate occured in vaccines which pharmacies could offer for free (Influenza 34%, PPSV23 16%, and Tdap 14%). The greatest reported barrier to vaccination was cost of vaccination.This study demonstrates the impact of a multidisciplinary approach involving rheumatology and community pharmacy.
To cite this abstract in AMA style:
Williams S, Garner S, Fifi-Mah A. VIVA QI: Vaccination In Vasculitis: Applying a Quality Improvement Approach [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/viva-qi-vaccination-in-vasculitis-applying-a-quality-improvement-approach/. Accessed .« Back to ACR Convergence 2024
ACR Meeting Abstracts - https://acrabstracts.org/abstract/viva-qi-vaccination-in-vasculitis-applying-a-quality-improvement-approach/